Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
Investing.com - Benchmark has reiterated its Speculative Buy rating and $8.00 price target on Heartbeam Inc. (NASDAQ:BEAT), currently trading at $1.27 with a market cap of $35.3 million, following the company’s second-quarter report. According to InvestingPro data, this target represents a 530% potential upside from current levels.
Heartbeam remains on track for its pilot commercial launch later this year after receiving FDA 510(k) clearance at the end of 2024 for its proprietary arrhythmia assessment system on a cable-free, patient-held device with 12-lead ECG accuracy.
The company’s second 510(k) application covering 12-lead synthesis software for arrhythmia assessment is expected to receive clearance by year-end, while discussions with the FDA on future clearances and indications, including ischemia, continue.
Heartbeam reduced its cash burn in the second quarter while preparing for its pilot launch with concierge practices in Florida and Southern California scheduled for later this year.
The company has seen accelerated interest from potential strategic partners regarding data and AI, complementary diagnostics and treatments, and distribution opportunities for its pocket-sized synthesized 12-lead ECG solution. For deeper insights into Heartbeam’s financial health and growth prospects, including 8 additional key ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, HeartBeam Inc. reported its second-quarter 2025 earnings, showing a slight earnings per share (EPS) beat. The company’s EPS came in at -$0.15, surpassing the forecasted -$0.16. This 6.25% positive surprise was supported by strategic cost-cutting measures. Despite the EPS beat, the company did not provide specific revenue figures for the quarter. Analysts had projected a more negative outcome, making the EPS result a noteworthy development for HeartBeam. This recent performance may influence future analyst assessments of the company. As of now, there have been no reported changes in analyst ratings or upgrades. Investors will likely keep an eye on any further strategic moves or financial updates from HeartBeam in the coming months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.